Expertise in

conditions

Federica Cavallo

Turin, IT

Clinical Trials:Currently Recruiting for 1 Trial

Expertise in

conditions

Turin, IT

Overview

Federica Cavallo practices in Turin, Italy. Ms. Cavallo is highly rated in 14 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Follicular Lymphoma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 230 peer reviewed articles and participating in 25 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Turin, 10126, Italy

Other Locations

Rome, 00168, Italy

Pescara, 65124, Italy

Bari, Italy

Sulmona, Italy

Chieti, Italy

Citta, Italy

Via Nizza, 10126, Italy

Orbassano, 10043, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

Enrollment Status: Recruiting

Publish Date: October 03, 2025

Intervention Type: Drug

Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin

Study Phase: Phase 2/Phase 3

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)

Enrollment Status: Completed

Publish Date: March 17, 2026

Intervention Type: Drug

Study Drugs: Ibrutinib, Rituximab

Study Phase: Phase 3

FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role: an International Multicenter Retrospective Analysis

Enrollment Status: Active_not_recruiting

Publish Date: January 23, 2026

IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)

Enrollment Status: Active_not_recruiting

Publish Date: January 15, 2026

Intervention Type: Radiation, Other

Study Phase: Not Applicable

Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Ibrutinib in Combination to Rituximab-CHOP Followed by Ibrutinib Maintenance in Untreated Patients With Activated-B-Cell (ABC)-DLBCL at Intermediate-high and High Risk (IPI ≥2)

Enrollment Status: Active_not_recruiting

Publish Date: December 24, 2025

Intervention Type: Drug

Study Drug: Ibrutinib

Study Phase: Phase 2

Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study by the Fondazione Italiana Linfomi.

Enrollment Status: Completed

Publish Date: December 24, 2025

Rituximab, Bendamustine and Cytarabine Followed by Venetoclax (V-RBAC) in High-risk Elderly Patients With Mantle Cell Lymphoma (MCL)

Enrollment Status: Completed

Publish Date: December 08, 2025

Intervention Type: Drug

Study Drug: Venetoclax

Study Phase: Phase 2

A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Drug

Study Drugs: R2-MANT, R-MANT

Study Phase: Phase 3

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Drug

Study Drugs: Romidepsin, CHOEP-21

Study Phase: Phase 1/Phase 2

Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Drug

Study Phase: Phase 3

View 9 Less Clinical Trials

230 Total Publications

"Summertime sadness": Striatal dopamine binding decreases during warmer seasons in patients with severe depression.

Journal: Psychiatry research. Neuroimaging

Published: November 29, 2025

View All 230 Publications

Frequently Asked Questions about Federica Cavallo

Is Federica Cavallo a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Federica Cavallo is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Federica Cavallo participate in research or clinical trials?

Yes. Federica Cavallo has published 230 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Federica Cavallo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Cavallo's expertise for a condition

ConditionClose